YK-11

Muscle Growth & Body Composition

Also known as: YK11, Myostine

Selective Androgen Receptor ModulatorsResearch phase: PreclinicalRegulatory: Not FDA-approved. WADA prohibited. Research chemical only. No human clinical trials.

Mechanism

YK-11 is a unique steroidal compound that acts as both a partial androgen receptor agonist and a myostatin inhibitor. By simultaneously activating AR in muscle tissue and inhibiting myostatin (the protein that limits muscle growth), it has a dual mechanism for promoting muscle hypertrophy. Its steroidal backbone and dual action make it distinct from classical non-steroidal SARMs.

Technical detail

YK-11 is a steroidal compound structurally related to 5α-dihydrotestosterone that functions as a partial AR agonist with the unique additional property of inducing follistatin expression, thereby inhibiting myostatin signaling through the ActRIIB-Smad2/3 pathway. In C2C12 myoblast studies, it upregulates follistatin mRNA and protein expression more potently than DHT. Its partial AR agonism combined with myostatin inhibition creates a dual anabolic mechanism. However, its steroidal structure means it may carry hepatotoxicity risk and endocrine suppression similar to oral anabolic steroids.